ALT5 Sigma (ALTS) Competitors $7.17 +0.21 (+3.02%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$7.33 +0.16 (+2.22%) As of 07/15/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. CGEM, RZLT, MBX, KMDA, TERN, RGNX, SVRA, TECX, PRTC, and FULCShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include Cullinan Therapeutics (CGEM), Rezolute (RZLT), MBX Biosciences (MBX), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), Savara (SVRA), Tectonic Therapeutic (TECX), PureTech Health (PRTC), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors Cullinan Therapeutics Rezolute MBX Biosciences Kamada Terns Pharmaceuticals REGENXBIO Savara Tectonic Therapeutic PureTech Health Fulcrum Therapeutics ALT5 Sigma (NASDAQ:ALTS) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has better earnings and valuation, ALTS or CGEM? ALT5 Sigma has higher revenue and earnings than Cullinan Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$12.53M9.99-$6.24MN/AN/ACullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.56 Do analysts recommend ALTS or CGEM? Cullinan Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 302.68%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ALTS or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -38.58%. Cullinan Therapeutics' return on equity of -29.47% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-38.58% -113.79% -8.96% Cullinan Therapeutics N/A -29.47%-28.19% Does the media prefer ALTS or CGEM? In the previous week, Cullinan Therapeutics had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 2 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.94 beat Cullinan Therapeutics' score of 0.94 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ALTS or CGEM? ALT5 Sigma has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ALTS or CGEM? 6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryCullinan Therapeutics beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$121.48M$7.75B$12.10B$9.29BDividend YieldN/A4.75%5.55%4.03%P/E RatioN/A18.1618.9919.58Price / Sales9.996.3026.4895.01Price / CashN/A22.4521.6257.93Price / Book14.632.722.275.54Net Income-$6.24M$308.89M$997.60M$257.73M7 Day Performance-6.40%0.12%-0.69%-0.08%1 Month Performance-24.53%10.92%2.92%8.09%1 Year PerformanceN/A16.40%540.23%13.02% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 Sigma0.1329 of 5 stars$7.17+3.0%N/AN/A$121.48M$12.53M0.00170CGEMCullinan Therapeutics1.7317 of 5 stars$7.45-5.3%$30.00+302.7%-55.1%$464.45MN/A-2.5630News CoverageRZLTRezolute2.5604 of 5 stars$5.11-3.9%$11.83+131.6%+5.4%$454.96MN/A-4.4440MBXMBX Biosciences1.7028 of 5 stars$13.40-3.4%$37.50+179.9%N/A$447.88MN/A0.0036KMDAKamada4.3088 of 5 stars$7.56-2.8%$13.00+72.0%+30.8%$447.39M$160.95M26.07360Positive NewsTERNTerns Pharmaceuticals3.8293 of 5 stars$5.05-1.2%$15.63+209.4%-49.4%$446.29MN/A-4.6340RGNXREGENXBIO3.9988 of 5 stars$8.24-5.3%$31.63+283.8%-36.0%$436.39M$83.33M-2.65370SVRASavara2.1685 of 5 stars$2.29-8.8%$5.60+144.5%-53.7%$433.82MN/A-4.7720TECXTectonic Therapeutic2.4872 of 5 stars$21.44-7.3%$83.60+289.9%+28.8%$431.71MN/A-2.93120Positive NewsPRTCPureTech Health2.4876 of 5 stars$17.66-0.8%$45.00+154.9%-22.1%$427.65M$4.83M0.00100News CoverageGap UpFULCFulcrum Therapeutics0.609 of 5 stars$7.84-0.8%$6.29-19.8%-7.2%$426.44M$80M-111.98100 Related Companies and Tools Related Companies CGEM Alternatives RZLT Alternatives MBX Alternatives KMDA Alternatives TERN Alternatives RGNX Alternatives SVRA Alternatives TECX Alternatives PRTC Alternatives FULC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALTS Stock Alerts